Every 8-K that Amicus Therapeutics, Inc (FOLD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FOLD filings page.
Amicus Therapeutics has completed its merger with BioMarin Pharmaceutical, becoming a wholly owned subsidiary of BioMarin. At closing, each share of Amicus common stock was converted into the right to receive $14.50 in cash per share, without interest and subject to tax withholding.
In connection with the merger, Amicus fully repaid and terminated all commitments under its October 2, 2023 Amicus Credit Agreement and released related guarantees and liens. The company notified Nasdaq of the merger, requested delisting of its common stock, and plans to terminate its SEC reporting obligations after the Form 25 and subsequent Form 15 become effective.
All Amicus directors and executive officers resigned at the merger’s effective time, with the former directors and officers of the merger subsidiary assuming equivalent roles. The company’s certificate of incorporation and bylaws were amended and restated to align with those of the merger subsidiary, reflecting its new status under BioMarin’s control.
Amicus Therapeutics, Inc. reports that the French Ministry of Economics and Finance granted clearance on April 23, 2026 for its planned merger with BioMarin Pharmaceutical under French foreign direct investment screening rules. This clearance satisfies the final outstanding regulatory condition to the merger, aside from items customarily completed at closing.
The merger, under which Amicus will become a wholly owned subsidiary of BioMarin, is now expected to close on April 27, 2026, subject to those remaining closing conditions. The company also reiterates that statements about the expected timing of completion are forward-looking and subject to various risks and uncertainties.
Amicus Therapeutics reported that its stockholders approved the company’s pending acquisition by BioMarin Pharmaceutical at a special meeting held on March 3, 2026. As of the January 28, 2026 record date, 313,918,463 shares of Amicus common stock were eligible to vote, and 234,785,243 shares, or about 74.79% of outstanding shares, were represented in person or by proxy.
Stockholders adopted the Agreement and Plan of Merger between Amicus, BioMarin and Lynx Merger Sub 1, Inc., with 234,593,492 votes for, 119,194 against and 72,557 abstentions. They also approved, on a non-binding advisory basis, certain merger-related compensation for named executive officers, with 209,150,012 votes for, 24,282,220 against and 1,353,011 abstentions.
The approval of the merger proposal satisfies the stockholder approval condition in the merger agreement. The companies noted that the U.S. Federal Trade Commission had already granted early termination of the Hart-Scott-Rodino waiting period on February 11, 2026. Completion of the transaction remains subject to other customary closing conditions, including regulatory clearances in specified non-U.S. jurisdictions, and is expected to close in the second quarter of 2026.
Amicus Therapeutics reported strong full-year 2025 growth and highlighted its pending acquisition by BioMarin. Net product revenue reached $634.2 million, up 20% year-over-year (17% at constant exchange rates), driven by Galafold at $521.7 million and Pombiliti + Opfolda at $112.5 million.
GAAP results improved to a net loss of $27.1 million, compared with larger losses in prior years, while non-GAAP net income was $96.8 million, or $0.31 per basic and diluted share. Cash and investments totaled $294 million, an increase of $44 million in 2025, and total assets were $949.9 million with stockholders’ equity of $274.2 million at year-end.
The company reiterated that the proposed acquisition by BioMarin is expected to close in Q2 2026, subject to closing conditions and approvals. Given the pending transaction, Amicus is not providing 2026 financial guidance and will not host its regular quarterly earnings conference call, directing investors instead to materials on its investor relations website.
Amicus Therapeutics provided preliminary, unaudited 2025 financial estimates in connection with its proposed acquisition by BioMarin Pharmaceutical. As of December 31, 2025, Amicus estimates it held approximately $294 million in cash, cash equivalents and marketable securities. For the year ended December 31, 2025, it estimates total net product revenues of about $634 million, including roughly $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.
The company stresses these figures are preliminary, unaudited and subject to normal closing procedures, with its auditor Ernst & Young LLP providing no assurance. Amicus warns that actual results may differ, that the estimates do not include all information needed to understand full-year performance, and that they should be read together with risk factor and forward‑looking statement disclosures, especially in the context of the pending merger and related shareholder vote.
Amicus Therapeutics (FOLD) furnished an update on its recent performance, announcing financial results for the quarter ended September 30, 2025. The company issued a press release and will host a conference call and webcast on November 4, 2025 to discuss third‑quarter results.
The materials were provided under Item 2.02 and are furnished, not filed. Attached exhibits include the press release (Exhibit 99.1) and conference call presentation materials (Exhibit 99.2).